Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 14/20 | 0.45 |
| ▸ | PDCD1 | Q15116 | 4/20 | 0.45 |
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.39 |
| ▸ | FFAR2 | O15552 | 5/20 | 0.39 |
| ▸ | EED | O75530 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24842594 | 1.00 | CD274 (0.45) | CD274PDCD1PDCD1LG2FFAR2EED | |
| SCHEMBL24843648 | 1.00 | CD274 (0.45) | CD274PDCD1PDCD1LG2FFAR2EED | |
| SCHEMBL24842605 | 1.00 | CD274 (0.45) | CD274PDCD1PDCD1LG2FFAR2EED | |
| SCHEMBL24842593 | 1.00 | CD274 (0.45) | CD274PDCD1PDCD1LG2FFAR2EED | |
| SCHEMBL26232741 | 0.96 | CD274 (0.42) | CD274PDCD1PDCD1LG2FFAR2 | |
| SCHEMBL26232743 | 0.96 | CD274 (0.42) | CD274PDCD1PDCD1LG2FFAR2 | |
| SCHEMBL26232735 | 0.96 | CD274 (0.42) | CD274PDCD1PDCD1LG2FFAR2 | |
| SCHEMBL26232744 | 0.96 | CD274 (0.42) | CD274PDCD1PDCD1LG2FFAR2 | |
| SCHEMBL26232748 | 0.96 | CD274 (0.42) | CD274PDCD1PDCD1LG2FFAR2 | |
| SCHEMBL24842654 | 0.92 | CD274 (0.42) | CD274PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760764-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230002413-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | ALIGOS THERAPEUTICS, INC. | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002413-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | CD274, PDCD1LG2, PDCD1 | CD274 1/4885PDCD1 3/4885PDCD1LG2 2/4885 |
| US-11760764-B2 | Methods and compositions for targeting PD-L1 | CD274, PDCD1LG2, PDCD1 | CD274 1/4885PDCD1 3/4885PDCD1LG2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.